Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $270
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Biogen (NASDAQ:BIIB) but lowers the price target from $290 to $270.

April 19, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Biogen but lowers the price target from $290 to $270.
While the reduction in price target could suggest a more cautious outlook on Biogen's short-term price potential, the maintenance of an Outperform rating indicates a continued positive long-term view on the stock by Oppenheimer. This mixed signal could lead to neutral short-term price movement as investors digest both the positive rating and the reduced price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100